Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Core Insights - Zymeworks Inc. presented six posters at the AACR Annual Meeting, showcasing advancements in their antibody-drug conjugate and T cell engager platforms, particularly highlighting the promising preclinical data for ZW209 in small cell lung cancer [1][2]. T Cell Engagers (TCE) - ZW209, a DLL3-targeted trispecific T cell engager, shows safety and potent preclinical efficacy in small cell lung cancer models, with an IND submission expected in the first half of 2026 [4][8]. - ZW171, a bispecific antibody targeting mesothelin, demonstrates anti-tumor activity across various cancers, including ovarian and pancreatic cancers, and is currently in a global Phase 1 clinical study [3][5]. Antibody-Drug Conjugates (ADCs) - ZW327, a novel Ly6E-targeting ADC, exhibits significant in vitro cytotoxicity against multiple tumor types, including breast and lung cancers, and shows robust anti-tumor activity in xenograft models [6][9]. - A biparatopic ADC targeting protein tyrosine kinase 7 (PTK7) has been developed, demonstrating improved binding and internalization compared to previous ADCs, with promising results in breast and lung cancer models [7][10]. Preclinical Development and Technologies - Zymeworks has developed high-throughput functional screening methods in 3D tumor models to enhance the evaluation of ADCs during preclinical development [11]. - In vitro assays have been created to predict ADC hematological toxicity, which could improve the selection of optimal linkers and payloads in ADC development [12][16]. Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for challenging diseases, including cancer and autoimmune conditions, leveraging its proprietary technologies [14][17].